# Teduglutide (Gattex)

> GLP-2 analog for short bowel syndrome dependent on parenteral support.

Source: https://peptides.cafe/peptide/teduglutide
Category: GLP-2 Analog · Gastrointestinal
Tag: FDA-Approved · GI

## Mechanism
Recombinant analog of glucagon-like peptide-2 with alanine→glycine substitution at position 2, resisting DPP-IV degradation; promotes intestinal mucosal growth, villus height, and absorptive capacity.

## Research areas
- Short bowel syndrome with intestinal failure
- Reduction of parenteral nutrition dependence

## Common research protocols
- Daily SC: 0.05 mg/kg subcutaneously once daily.

## Study summaries
- "STEPS trial" — Gastroenterology (2012): Reduced parenteral support volume in SBS patients vs placebo.

## Considerations
- FDA-approved.
- Colorectal polyp surveillance required.
- Risk of intestinal obstruction and biliary/pancreatic disease.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.